Target Price | $38.76 |
Price | $13.62 |
Potential |
184.69%
register free of charge
|
Number of Estimates | 27 |
27 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .
The average Sarepta Therapeutics, Inc. target price is $38.76.
This is
184.69%
register free of charge
$194.25
1,326.74%
register free of charge
$10.10
25.82%
register free of charge
|
|
A rating was issued by 33 analysts: 19 Analysts recommend Sarepta Therapeutics, Inc. to buy, 13 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of
184.69%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 1.90 | 2.28 |
52.97% | 19.93% | |
EBITDA Margin | 11.59% | -3.94% |
154.13% | 133.99% | |
Net Margin | 12.37% | -17.96% |
128.69% | 245.21% |
26 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.18 | -4.17 |
137.59% | 291.28% | |
P/E | negative | |
EV/Sales | 0.86 |
29 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Needham |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
Leerink Swann |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Needham |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Analyst Rating | Date |
---|---|
Locked
Needham:
Locked
➜
Locked
|
Jul 22 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Jul 22 2025 |
Locked
Leerink Swann:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
Needham:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.